Digoxin
- Generic Name
- Digoxin
- Brand Names
- Digox, Lanoxin
- Drug Type
- Small Molecule
- Chemical Formula
- C41H64O14
- CAS Number
- 20830-75-5
- Unique Ingredient Identifier
- 73K4184T59
- Background
Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954.
...
- Indication
Digoxin is indicated in the following conditions: 1) For the treatment of mild to moderate heart failure in adult patients. 2) To increase myocardial contraction in children diagnosed with heart failure. 3) To maintain control ventricular rate in adult patients diagnosed with chronic atrial fibrillation.
...
- Associated Conditions
- Myocardial contractility, Ventricular Arrhythmia, Mild to moderate heart failure
- Associated Therapies
- -
A Phase 2 Efficacy Study of CLS003 ICVT in Subjects With Cutaneous Warts.
- Conditions
- Interventions
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2016-07-28
- Lead Sponsor
- Maruho Co., Ltd.
- Target Recruit Count
- 81
- Registration Number
- NCT02333643
- Locations
- 🇳🇱
LUMC/Centre for Human Drug Research, Leiden, Netherlands
Drug-Drug Interaction Study in Health Adult Volunteers
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2014-10-24
- Lead Sponsor
- Kowa Research Institute, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02273986
- Locations
- 🇺🇸
PPD, Austin, Texas, United States
Phase 1 Drug Interaction Study of the Effect of Apixaban on the PK of Digoxin in Healthy Subjects
- First Posted Date
- 2014-10-13
- Last Posted Date
- 2015-08-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 24
- Registration Number
- NCT02262520
The Effect of BI 187004 on the Pharmacokinetics of Cytochrome P450 Substrates (Caffeine, Warfarin, Omeprazole, Metoprolol and Midazolam) and a P Glycoprotein Substrate (Digoxin)
- Conditions
- Interventions
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02254148
- Locations
- 🇩🇪
1307.19.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-09-26
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 32
- Registration Number
- NCT02249910
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
Acute Cardioversion Versus Wait And See-approach for Symptomatic Atrial Fibrillation in the Emergency Department
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2020-01-21
- Lead Sponsor
- Maastricht University Medical Center
- Target Recruit Count
- 437
- Registration Number
- NCT02248753
- Locations
- 🇳🇱
VU University Medical Center, Amsterdam, Netherlands
🇳🇱Antonius Ziekenhuis, Sneek, Netherlands
🇳🇱University Medical Center Groningen, Groningen, Netherlands
Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 31
- Registration Number
- NCT02243098
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
Drug-drug Interaction Between Digoxin, Furosemide, Metformin, and Rosuvastatin
- Conditions
- Interventions
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02231931
- Locations
- 🇩🇪
352.2082.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
A Phase 1 Drug-drug Interaction Study in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-08-27
- Last Posted Date
- 2014-11-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 20
- Registration Number
- NCT02227173
- Locations
- 🇺🇸
Healthcare Discoveries, LLC d/b/a ICON Development Solutions, San Antonio, Texas, United States
Phase II Multicentric Study of Digoxin Per os in Classic or Endemic Kaposi' s Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2014-08-08
- Last Posted Date
- 2018-07-23
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 17
- Registration Number
- NCT02212639
- Locations
- 🇫🇷
Saint-Louis Hospital, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.